Leerink Partnrs Issues Optimistic Outlook for EWTX Earnings

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) - Stock analysts at Leerink Partnrs boosted their Q1 2025 EPS estimates for shares of Edgewise Therapeutics in a research report issued to clients and investors on Wednesday, April 2nd. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.44) per share for the quarter, up from their previous forecast of ($0.45). The consensus estimate for Edgewise Therapeutics' current full-year earnings is ($1.45) per share. Leerink Partnrs also issued estimates for Edgewise Therapeutics' Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.00) EPS and FY2026 earnings at ($1.95) EPS.

Several other brokerages have also recently issued reports on EWTX. Royal Bank of Canada dropped their target price on shares of Edgewise Therapeutics from $56.00 to $52.00 and set an "outperform" rating on the stock in a report on Thursday, April 3rd. Piper Sandler reiterated an "overweight" rating and set a $51.00 price objective on shares of Edgewise Therapeutics in a research note on Wednesday, April 2nd. Evercore ISI upped their target price on Edgewise Therapeutics from $45.00 to $50.00 and gave the stock an "outperform" rating in a report on Tuesday, December 17th. Stifel Nicolaus assumed coverage on Edgewise Therapeutics in a report on Wednesday, January 22nd. They issued a "hold" rating and a $30.00 price target on the stock. Finally, Scotiabank downgraded Edgewise Therapeutics from a "sector outperform" rating to a "sector perform" rating and cut their price target for the company from $50.00 to $14.00 in a report on Wednesday, April 2nd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $40.38.

Remove Ads

Edgewise Therapeutics Trading Down 1.3 %

Shares of Edgewise Therapeutics stock traded down $0.15 during trading on Monday, hitting $11.42. 1,278,119 shares of the stock traded hands, compared to its average volume of 1,120,847. Edgewise Therapeutics has a 52-week low of $10.60 and a 52-week high of $38.12. The stock's fifty day simple moving average is $22.90 and its 200 day simple moving average is $27.78. The firm has a market cap of $1.20 billion, a P/E ratio of -7.61 and a beta of 0.32.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.03).

Insider Transactions at Edgewise Therapeutics

In other Edgewise Therapeutics news, Director Orbimed Advisors Llc purchased 496,771 shares of the company's stock in a transaction dated Thursday, April 3rd. The shares were acquired at an average price of $20.13 per share, for a total transaction of $10,000,000.23. Following the completion of the purchase, the director now owns 14,809,075 shares of the company's stock, valued at approximately $298,106,679.75. The trade was a 3.47 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CMO Joanne M. Donovan sold 25,000 shares of the company's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $27.63, for a total transaction of $690,750.00. Following the transaction, the chief marketing officer now owns 16,358 shares in the company, valued at approximately $451,971.54. This trade represents a 60.45 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,836 shares of company stock valued at $986,245. Corporate insiders own 24.11% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of EWTX. Summit Investment Advisors Inc. lifted its stake in shares of Edgewise Therapeutics by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,594 shares of the company's stock worth $203,000 after buying an additional 482 shares during the period. Alliancebernstein L.P. lifted its position in Edgewise Therapeutics by 1.7% during the 4th quarter. Alliancebernstein L.P. now owns 77,260 shares of the company's stock worth $2,063,000 after acquiring an additional 1,300 shares during the period. Diadema Partners LP acquired a new stake in Edgewise Therapeutics during the 4th quarter worth about $36,000. Rhumbline Advisers grew its stake in Edgewise Therapeutics by 1.5% during the 4th quarter. Rhumbline Advisers now owns 102,397 shares of the company's stock valued at $2,734,000 after purchasing an additional 1,525 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Edgewise Therapeutics by 4.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 41,313 shares of the company's stock valued at $1,103,000 after purchasing an additional 1,595 shares during the period.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.